Navigation Links
Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

al achieved the primary endpoint of median Time to Last Unformed Stool (TLUS). Median TLUS for patients treated with prulifloxacin was 32.8 hours which was statistically significant compared to the TLUS for placebo with a p-value of less than 0.0001. Prulifloxacin was generally well tolerated and had a similar safety profile compared to placebo. This is the second of two pivotal Phase 3 clinical studies which will be used to support an NDA submission with the U.S. Food and Drug Administration.
  • Raised $32.9 million in gross proceeds through the sale of 3.3 million shares and warrants to purchase 91,533 shares in a registered direct offering in March 2009.
  • Appointed Francois-Xavier Frapaise, M.D., as Senior Vice President and Chief Scientific Officer and Peter E. Grebow, Ph.D., Executive Vice President of Worldwide Technical Operations at Cephalon, Inc. (Nasdaq: CEPH), to the company's Board of Directors.
  • Published in vitro data highlighting the antibacterial activity of prulifloxacin in the peer-reviewed journal Antimicrobial Agents and Chemotherapy.

  • About Optimer Pharmaceuticals

    Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
    2. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
    3. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
    4. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
    5. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
    6. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
    7. Idenix Pharmaceuticals Reports First Quarter Financial Results
    8. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
    9. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
    10. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
    11. Vanda Pharmaceuticals Reports First Quarter 2009 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... ... 30, 2015 , ... GEA's Pony™ NS2006L is ... up to 1500 bar. The sanitary design gauge of the NS2006L is well ... The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
    (Date:7/29/2015)... , July 30, 2015 According ... Market - Growth, Trends & Forecasts (2015-2020), , published by ... US$ 30.25 billion by the end of 2020, with ... accounting for more than 40% of the global market size. ... at a CAGR of 13.7% during the period of (2015-2020). ...
    (Date:7/29/2015)... MONTREAL , July 29, 2015 /PRNewswire/ - BioAmber Inc. ... Laurin , the Company,s Chief Financial Officer has resigned.  ... former Chief Financial Officer who retired in December 2014, ... search for a permanent successor.     Andy ... Mr. Laurin and ensure a smooth transition.  Andy was ...
    (Date:7/29/2015)... Station, TX (PRWEB) , ... July 29, 2015 ... ... POD® designer, manufacturer and supplier, announces the launch of their 2nd generation cell ... to the current miniPOD CT, but it also represents a new POD® design. ...
    Breaking Biology Technology:GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3
    ... BEIJING, Nov. 4, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. ... leading plasma-based biopharmaceutical companies in China, today announced that it ... 2011 financial results on Tuesday, November 8, 2011 at 8:00 ... China on the same day. Hosting the call ...
    ... Major milestone achieved in the commercial launch of ... ascites due to liver cirrhosis. Sequana Medical, ... (AKH Wien) reported that the first two commercial implants ... General Hospital in October, under the supervision of Univ. ...
    ... Nov. 3, 2011 Cumberland Pharmaceuticals Inc. (NASDAQ: ... hospital acute care and gastroenterology markets, today announced third quarter ... the three months ended September 30, 2011, net revenue was ... period. The growth in net revenue was driven by an ...
    Cached Biology Technology:China Biologic to Host Earnings Conference Call on November 8, 2011 at 8:00 a.m. EST (NY) 2The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medical's ALFApump® System 2Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 7Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 8Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 9Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 10Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 11Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 12
    (Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
    (Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
    (Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
    Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
    ... A new approach to mapping how proteins interact with ... Studies, could aid in the design of new drugs ... proteins using artificial amino acids, the Salk scientists determine ... its ligand, the molecule that turns it on. The ...
    ... leaf fragment collected decades ago on a Virginia canal bank ... plants, a 115- to 125-million-year-old species new to science. The ... a new question in the study of plant evolution: did ... distinctive pollen? Or did pollen come later? The find ...
    ... 2013 The American Association for the Advancement of Science ... Programme at EMBO, to its 2013 class of fellows. Election ... members by their peers and acknowledges contributions that help to ... by AAAS for her work looking at the societal impact ...
    Cached Biology News:Salk scientists crack riddle of important drug target 2Salk scientists crack riddle of important drug target 3Evolution, Civil War history entwine in plant fossil with a tragic past 2Evolution, Civil War history entwine in plant fossil with a tragic past 3